Lixte Biotechnology Files 8-K on Definitive Agreement & Equity Sales
Ticker: LIXT · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $2.415, $2.29, $1,050,000 b, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: definitive-agreement, equity-sale
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K for a material agreement and equity sales on Feb 11.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on February 11, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. The company, incorporated in Delaware, filed this 8-K report on February 13, 2025. Specific details regarding the agreement and sales were not provided in the excerpt.
Why It Matters
This filing indicates significant corporate actions by Lixte Biotechnology, potentially impacting its financial structure and future operations.
Risk Assessment
Risk Level: medium — Filings related to definitive agreements and equity sales can introduce financial and operational risks for the company and its investors.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- February 11, 2025 (date) — Earliest event reported
- February 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the nature of the material definitive agreement entered into by Lixte Biotechnology Holdings, Inc. on February 11, 2025?
The provided excerpt does not specify the details of the material definitive agreement.
What type of equity securities were sold in the unregistered sales reported on February 11, 2025?
The filing mentions unregistered sales of equity securities, but the specific type is not detailed in the excerpt.
What is the IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc.?
The IRS Employer Identification Number for Lixte Biotechnology Holdings, Inc. is 20-2903526.
What is the business address of Lixte Biotechnology Holdings, Inc.?
The business address is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
When did Lixte Biotechnology Holdings, Inc. change its former name from SRKP 7 INC?
The date of the name change from SRKP 7 INC was August 3, 2005.
Filing Stats: 1,590 words · 6 min read · ~5 pages · Grade level 12 · Accepted 2025-02-13 10:45:10
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock"), at an o
- $2.415 — Common Stock"), at an offering price of $2.415 per share, and (b) in a concurrent priv
- $2.29 — s from issuance at an exercise price of $2.29 per share. The Common Stock Warrants an
- $1,050,000 b — lted in gross proceeds of approximately $1,050,000 before deducting the placement agent's fe
- $15,000 — Offering, and paid the Placement Agent $15,000 for non-accountable expenses and $10,00
- $10,000 — 15,000 for non-accountable expenses and $10,000 for clearing fees. On the Closing Dat
- $3.0188 — nt's Warrants have an exercise price of $3.0188 per share, and a term of five years for
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex4-1.htm (EX-4.1) — 116KB
- ex4-2.htm (EX-4.2) — 107KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-1.htm (EX-10.1) — 286KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-2.htm (EX-99.2) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 5KB
- ex5-1_003.jpg (GRAPHIC) — 6KB
- ex5-1_002.jpg (GRAPHIC) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-25-006285.txt ( ) — 982KB
- lixt-20250211.xsd (EX-101.SCH) — 3KB
- lixt-20250211_def.xml (EX-101.DEF) — 29KB
- lixt-20250211_lab.xml (EX-101.LAB) — 36KB
- lixt-20250211_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 13, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ Bastiaan van der Baan Bastiaan van der Baan Chief Executive Officer 4 INDEX TO EXHIBITS Exhibit No. Description 4.1 Form of Common Stock Warrant 4.2 Form of Placement Agent's Warrants 5.1 Opinion of TroyGould PC 10.1 Form of Securities Purchase Agreement 99.1 Press Release dated February 11, 2025 99.2 Press Release dated February 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 5